Roche: positive long-term data in SMA
(CercleFinance.com) - At the Muscular Dystrophy Association (MDA) conference, Roche announces new positive long-term data for Evrysdi (risdiplam) in people aged two to 25 years with spinal muscular atrophy (SMA) types 2 and 3.
Data from the pivotal SUNFISH study confirmed that increases in motor function were maintained at four years and that the overall rate of adverse events continued to decrease over the 48-month period.
Participants also reported a continued improvement or stabilisation in the independent performance of activities of daily living, such as eating, drinking and picking up and moving objects.
Over 8,500 people, from newborns to the over-60s, have been treated with Evrysdi, which is now approved in more than 90 countries worldwide and is currently under review in another 16 countries.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Data from the pivotal SUNFISH study confirmed that increases in motor function were maintained at four years and that the overall rate of adverse events continued to decrease over the 48-month period.
Participants also reported a continued improvement or stabilisation in the independent performance of activities of daily living, such as eating, drinking and picking up and moving objects.
Over 8,500 people, from newborns to the over-60s, have been treated with Evrysdi, which is now approved in more than 90 countries worldwide and is currently under review in another 16 countries.
Copyright (c) 2023 CercleFinance.com. All rights reserved.